Johnson & Johnson (JNJ) News $JNJ
5 Bulletproof Dividend Stocks for Uncertain Times
Andrés Cardenal, The Motley Fool - Motley Fool - Sat Mar 22, 6:30AM CDT
Source: YCharts. The situation in Crimea is becoming increasingly unstable, and the stock market looks vulnerable to all kinds of risks after five years of one of the biggest bull runs in history. Nobody knows for certain how the markets may...
Good News for Johnson & Johnson - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:30PM CDT
Johnson & Johnson halted an early phase III study on a three-month formulation of Invega Sustenna.
Biotechs, Medicals Get Hurt Amid Price-Inquiry News
at Investor's Business Daily - Fri Mar 21, 5:26PM CDT
Two normally healthy biotech stocks suffered critical declines Friday, while most other medical names on the IBD 50 remained in fairly stable condition. Still, the biotech illness spread to other drug stocks. As a result, six of the seven biggest...
Final Glance: Pharmaceuticals companies
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Johnson & Johnson Rises 1.92% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Mar 21, 3:41PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $93.88 to a high of $95.93. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $94.36 on volume of 23.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 1.92% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Mar 21, 3:40PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $93.88 to a high of $95.93. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $94.36 on volume of 23.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Medivation, Inc: Fast Growing Drugs That May Become Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 21, 1:30PM CDT
Blockbuster status -- the gold medal term awarded to therapies racking up sales of more than $1 billion per year -- is the Holy Grail for drug developers. Arguably, it's the chance to discover blockbusters that fuels industry R&D spend and...
Midday Glance: Pharmaceuticals companies
AP - Fri Mar 21, 12:24PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri Mar 21, 12:24PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Better Buy: Johnson & Johnson vs. Amazon.com
Michael Finarelli and David Williamson, The Motley Fool - Motley Fool - Fri Mar 21, 11:00AM CDT
In today's first-round matchup of The Motley Fool Better Buy Tournament, Johnson & Johnson squares off against Amazon.com in a battle to determine which stock is the better buy now. The 64-company tournament pits two Motley Fool analysts...
Early Glance: Medical Devices companies
AP - Fri Mar 21, 9:46AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Early Glance: Pharmaceuticals companies
AP - Fri Mar 21, 9:46AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Next Resistance Level for Johnson & Johnson (JNJ) is $95.00
Comtex SmarTrend(R) - Fri Mar 21, 9:33AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today above their pivot of $93.77 and have already reached the first level of resistance at $94.57. Should the shares continue to rise, the resistance pivots of $95.00 and $96.23 will be of interest.
Can These Companies Bounce Back from Disappointing Sales?
Dan Carroll, The Motley Fool - Motley Fool - Fri Mar 21, 8:30AM CDT
Bristol-Myers Squibb and Pfizer have rallied back from the patent cliff as well as any companies in big pharma, and both these standout firms have looked toward the future in igniting investor optimism. But one drug captured all the hype around...
Concise Analysis of the International China Spectacles Industry
M2 - Fri Mar 21, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sv3rl4/china_spectacles) has announced the addition of the "Concise Analysis of the International China Spectacles Industry" report to their offering. From 2003 to 2007, the spectacles output in China climbed from 552 million pairs to 730.7 million pairs, with the CAGR of 7.8%. However, the global economic chaos brought with a massive decline in output between 2008 and 2012, with the figure in 2012 slumping to 546 million pairs. Nevertheless, given the large cardinal number of Chinese population, there are three to four million Chinese people in need for corrective glasses, with the annual demand approaching 100 million pairs. In the meantime, China has become the world's third largest luxury consumer, as high-consumption population is skyrocketing. This will come as a trend of increasing demand for diversified and personalized spectacles. China spectacles industry is expected to see a great potential in future. In China spectacles market, large-sized and foreign enterprises present more competitive. In 2012, large industrial players which stood at 4.2% of total number of enterprises contributed 26.8% of the total revenue in the industry, while small ones which made up 66% of enterprise quantity claimed 39.7% of the total revenue. Thus far, foreign brands including Zeiss, Essilor and Hoya are well received by Chinese consumers, while domestic brands like Conant and WX are gaining increasing acclaims. The production of lens is the key to the production of spectacles. Lenses are mainly made from optical glass, polycarbonate (PC) and polymethyl methacrylate (PMMA). In particular, optical glass is mostly made in China, while PC and PMMA are heavily reliant on import. In 2013Q1-Q3, China imported 1,025,300 tons of PC and 164,700 tons of PMMA respectively. Key Topics Covered: 1. Spectacles Industry 2. Development of China Spectacles Industry 3. Upstream Industry 4. Major Industrial Players Companies Mentioned: - Arts Optical - Baodao - Bausch & Lomb - Carl Zeiss Group - Chemi Lens - Daming Optical - Elegance International - Essilor - HOYA - Johnson & Johnson - Luxottica - Qianye - Shanghai Conant Optics - Sun Hing Vision Group Holdings For more information visit http://www.researchandmarkets.com/research/sv...spectacles
Johnson & Johnson to Webcast Annual Meeting of Shareholders
PR Newswire - Fri Mar 21, 6:45AM CDT
Johnson & Johnson (NYSE: JNJ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 24, 2014, from the Hyatt Regency Hotel in New Brunswick, N.J.
Court overturns J&J ruling
at Investor's Business Daily - Thu Mar 20, 5:47PM CDT
The Ark. Supreme Court overturned a $1.2 bil ruling against Johnson & Johnson's (JNJ) marketing of its antipsychotic drug Risperdal. The court said the pharmaceutical company was sued by the state using a law that applies only to health care...
Ranking Big Pharma's Top Drugs of 2013
Max Macaluso, The Motley Fool - Motley Fool - Thu Mar 20, 5:30PM CDT
In 2012, AbbVie 's Humira brought in $9.3 billion in total sales and was the best selling drug in the world. But did the autoimmune disease drug, which accounts for more than half of AbbVie's sales, keep its crown in 2013? In the following...
5 Bulletproof Dividend Stocks for Uncertain Times
Andrés Cardenal, The Motley Fool - Motley Fool - Sat Mar 22, 6:30AM CDT
Source: YCharts. The situation in Crimea is becoming increasingly unstable, and the stock market looks vulnerable to all kinds of risks after five years of one of the biggest bull runs in history. Nobody knows for certain how the markets may...
Good News for Johnson & Johnson - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:30PM CDT
Johnson & Johnson halted an early phase III study on a three-month formulation of Invega Sustenna.
Biotechs, Medicals Get Hurt Amid Price-Inquiry News
at Investor's Business Daily - Fri Mar 21, 5:26PM CDT
Two normally healthy biotech stocks suffered critical declines Friday, while most other medical names on the IBD 50 remained in fairly stable condition. Still, the biotech illness spread to other drug stocks. As a result, six of the seven biggest...
Final Glance: Pharmaceuticals companies
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Johnson & Johnson Rises 1.92% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Mar 21, 3:41PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $93.88 to a high of $95.93. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $94.36 on volume of 23.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 1.92% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Mar 21, 3:40PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $93.88 to a high of $95.93. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $94.36 on volume of 23.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Medivation, Inc: Fast Growing Drugs That May Become Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 21, 1:30PM CDT
Blockbuster status -- the gold medal term awarded to therapies racking up sales of more than $1 billion per year -- is the Holy Grail for drug developers. Arguably, it's the chance to discover blockbusters that fuels industry R&D spend and...
Midday Glance: Pharmaceuticals companies
AP - Fri Mar 21, 12:24PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri Mar 21, 12:24PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Better Buy: Johnson & Johnson vs. Amazon.com
Michael Finarelli and David Williamson, The Motley Fool - Motley Fool - Fri Mar 21, 11:00AM CDT
In today's first-round matchup of The Motley Fool Better Buy Tournament, Johnson & Johnson squares off against Amazon.com in a battle to determine which stock is the better buy now. The 64-company tournament pits two Motley Fool analysts...
Early Glance: Medical Devices companies
AP - Fri Mar 21, 9:46AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Early Glance: Pharmaceuticals companies
AP - Fri Mar 21, 9:46AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Next Resistance Level for Johnson & Johnson (JNJ) is $95.00
Comtex SmarTrend(R) - Fri Mar 21, 9:33AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today above their pivot of $93.77 and have already reached the first level of resistance at $94.57. Should the shares continue to rise, the resistance pivots of $95.00 and $96.23 will be of interest.
Can These Companies Bounce Back from Disappointing Sales?
Dan Carroll, The Motley Fool - Motley Fool - Fri Mar 21, 8:30AM CDT
Bristol-Myers Squibb and Pfizer have rallied back from the patent cliff as well as any companies in big pharma, and both these standout firms have looked toward the future in igniting investor optimism. But one drug captured all the hype around...
Concise Analysis of the International China Spectacles Industry
M2 - Fri Mar 21, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sv3rl4/china_spectacles) has announced the addition of the "Concise Analysis of the International China Spectacles Industry" report to their offering. From 2003 to 2007, the spectacles output in China climbed from 552 million pairs to 730.7 million pairs, with the CAGR of 7.8%. However, the global economic chaos brought with a massive decline in output between 2008 and 2012, with the figure in 2012 slumping to 546 million pairs. Nevertheless, given the large cardinal number of Chinese population, there are three to four million Chinese people in need for corrective glasses, with the annual demand approaching 100 million pairs. In the meantime, China has become the world's third largest luxury consumer, as high-consumption population is skyrocketing. This will come as a trend of increasing demand for diversified and personalized spectacles. China spectacles industry is expected to see a great potential in future. In China spectacles market, large-sized and foreign enterprises present more competitive. In 2012, large industrial players which stood at 4.2% of total number of enterprises contributed 26.8% of the total revenue in the industry, while small ones which made up 66% of enterprise quantity claimed 39.7% of the total revenue. Thus far, foreign brands including Zeiss, Essilor and Hoya are well received by Chinese consumers, while domestic brands like Conant and WX are gaining increasing acclaims. The production of lens is the key to the production of spectacles. Lenses are mainly made from optical glass, polycarbonate (PC) and polymethyl methacrylate (PMMA). In particular, optical glass is mostly made in China, while PC and PMMA are heavily reliant on import. In 2013Q1-Q3, China imported 1,025,300 tons of PC and 164,700 tons of PMMA respectively. Key Topics Covered: 1. Spectacles Industry 2. Development of China Spectacles Industry 3. Upstream Industry 4. Major Industrial Players Companies Mentioned: - Arts Optical - Baodao - Bausch & Lomb - Carl Zeiss Group - Chemi Lens - Daming Optical - Elegance International - Essilor - HOYA - Johnson & Johnson - Luxottica - Qianye - Shanghai Conant Optics - Sun Hing Vision Group Holdings For more information visit http://www.researchandmarkets.com/research/sv...spectacles
Johnson & Johnson to Webcast Annual Meeting of Shareholders
PR Newswire - Fri Mar 21, 6:45AM CDT
Johnson & Johnson (NYSE: JNJ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 24, 2014, from the Hyatt Regency Hotel in New Brunswick, N.J.
Court overturns J&J ruling
at Investor's Business Daily - Thu Mar 20, 5:47PM CDT
The Ark. Supreme Court overturned a $1.2 bil ruling against Johnson & Johnson's (JNJ) marketing of its antipsychotic drug Risperdal. The court said the pharmaceutical company was sued by the state using a law that applies only to health care...
Ranking Big Pharma's Top Drugs of 2013
Max Macaluso, The Motley Fool - Motley Fool - Thu Mar 20, 5:30PM CDT
In 2012, AbbVie 's Humira brought in $9.3 billion in total sales and was the best selling drug in the world. But did the autoimmune disease drug, which accounts for more than half of AbbVie's sales, keep its crown in 2013? In the following...
